02565 派格生物醫藥－Ｂ
PEGBIO CO-B
PEGBIO CO-B
| Listing Date | 2025/05/27 |
| Listing Price | 15.600 |
Quote
Subscription Result
- Subscription Rate743.78x
- Guarantee One Lot Size200 lot
- One Lot Success Rate8%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
PegBio Co., Ltd. was founded in 2008, it is a biotechnology company focused on the in-house discovery and development of innovative therapies, primarily peptide and small molecule drugs, for chronic diseases with a particular emphasis on metabolic disorders.
--
The Group have self-developed one Core Product and other five product candidates to capture the market potential in prevalent chronic and metabolic diseases, including type 2 diabetes mellitus, obesity, non-alcoholic steatohepatitis, opioid-induced constipation and congenital hyperinsulinemia.
--
The Group’s Core Product, PB-119, is a self-developed, near-commercialized, long-acting GLP-1 receptor agonist primarily designed for the first-line treatment of T2DM and obesity. The new drug application for PB-119 in China for T2DM was accepted by the NMPA in September 2023. The Group expect to receive the NDA approval and commercially launch PB-119 for the treatment of T2DM in China in 2025.
--
As of May 12, 2025, the Group held 83 patents and patent applications, including 13 patents and 15 patent applications in relation to its Core Product, and all of its material patents and patent applications were self-owned.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 500 |
GLOBAL OFFERING
| No. of Offer Shares | 19.28M H shares |
| No. of International Offer Shares | 9.64M H shares |
| No. of HK Offer Shares | 9.64M H shares |
| Offer Price | $15.60 |
| Stock Code | 2565 |
| Sponsor(s) | China International Capital Corporation Hong Kong Securities Limited |
| Underwriter(s) | China International Capital Corporation Hong Kong Securities Limited, CMBC Securities Company Limited, ABCI Securities Company Limited, BOCI Asia Limited, CCB International Capital Limited, Livermore Holdings Limited, Zhongtai International Securities Limited, SPDB International Capital Limited, Eddid Securities and Futures Limited, Sinolink Securities (Hong Kong) Company Limited, China Everbright Securities (HK) Limited, GF Securities (Hong Kong) Brokerage Limited, China Galaxy International Securities (Hong Kong) Co., Limited, CEB International Capital Corporation Limited |
TIME TABLE
| Application Period | May 19 (Mon) - noon, May 22 (Thu) |
| Price Determination Date | -- |
| Result Announcement Date | On or before May 26 (Mon) |
| Result Announcement Date | On or before May 26 (Mon) |
| Result Announcement Date | On or before May 27 (Tue) |
| Dealings in Shares commence on | May 27, 2025. (Tue) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $15.60 |
| Capitalization (H Shares) | 6.02B |
| NAV / share ($) | $0.84 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 15.60, the net proceeds raised would be HKD 231.80M, of which |
| 50.2% : Fund the commercialization and indication expansion of Core Product PB-119 |
| 34.5% : Fund further development of key product PB-718 |
| 5.3% : Fund ongoing and planned research and development of our other pipeline product candidates |
| 1% : Business development activities and enhancing overseas presence |
| 9% : Working capital |
IPO NEWS
| 27/05/2025 16:08 |
| {New Stock}PEGBIO CO-B(02565) ends down 25.9% at HK$11.56 |
| 27/05/2025 09:20 |
| {New Stock}PEGBIO CO-B(02565) opens down 16.67% at HK$13 |
| 26/05/2025 18:35 |
| {New Stock}PEGBIO CO-B(02565) ends down 3.72% on grey market |
| 26/05/2025 16:20 |
| {New Stock}PEGBIO CO-B down 3.21% at HK$15.1 on grey market |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).